Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CaboRISE: Cabozantinib Dose Escalation in Advanced HCC
NCT04522908Phase 2Completed
- Sponsor
- Institut für Klinische Krebsforschung
- Start
- Oct 2020
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cabozantinib in hepatocellular carcinoma (HCC), sponsored by Institut für Klinische Krebsforschung. Started Oct 2020; status: completed.
02
Drugs
cabozantinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04522908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04522908.